China outbound M&A plummets to 10-year low on trade tensions


Chinese acquirers announced $41 billion in outbound deals this year, nearly halving from 2018 and less than a fifth of the 2016 peak, showed data from Refinitiv. The number was only slightly higher than 2009 when dealmaking plunged after the financial crisis. Outbound deals into the United States dropped 80% this year from last to $2 billion.

HONG KONG: China's outbound mergers and acquisitions (M&As) clocked their weakest year in a decade in 2019, as an escalated U.S.-China trade war and tightened regulatory scrutiny of Chinese companies impacted appetite for overseas dealmaking.

Chinese acquirers announced $41 billion in outbound deals this year, nearly halving from 2018 and less than a fifth of the 2016 peak, showed data from Refinitiv. The number was only slightly higher than 2009 when dealmaking plunged after the financial crisis.

Get 20% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
mergers , acquisitions , outbound , China , trade war

Next In Business News

Hong Kong Monetary Authority raises interest rates, tracking Fed move
Singapore's August exports surge by 46.2% yr/yr� as AI boom powers demand
Budget 2027: Targeted incentives needed to attract regional institutional investors to Malaysian equities
Pioneer Heat makes positive ACE Market debut
Batik Air says it can bring aircraft in quickly to absorb domestic market demand if required
FBM KLCI rebounds from weak start after Fed rate hike
Ringgit opens slightly lower vs US dollar after hawkish FOMC outcome
Fed hikes rates, sees more tightening in search of 'timelier' drop in inflation
Trading ideas: AirAsia, PTT Synergy, Frontken, Crest Builder, EcoWorld Malaysia, YTL Power, Hextar Retail
Spain’s ultra rich pharma family eyes drug investments

Others Also Read